Trexquant Investment LP Has $1.62 Million Holdings in SiBone $SIBN

Trexquant Investment LP increased its stake in shares of SiBone (NASDAQ:SIBN) by 31.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 115,114 shares of the company’s stock after purchasing an additional 27,331 shares during the period. Trexquant Investment LP owned approximately 0.27% of SiBone worth $1,615,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SIBN. Dimensional Fund Advisors LP grew its stake in shares of SiBone by 10.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 354,835 shares of the company’s stock worth $4,974,000 after purchasing an additional 34,512 shares during the period. Price T Rowe Associates Inc. MD grew its stake in SiBone by 11.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 31,742 shares of the company’s stock valued at $446,000 after acquiring an additional 3,318 shares during the period. Northern Trust Corp grew its stake in SiBone by 6.3% in the fourth quarter. Northern Trust Corp now owns 409,122 shares of the company’s stock valued at $5,736,000 after acquiring an additional 24,214 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in SiBone in the fourth quarter valued at about $426,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in SiBone in the fourth quarter valued at about $210,000. 98.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Anthony J. Recupero sold 3,833 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.62, for a total transaction of $59,871.46. Following the sale, the insider owned 275,288 shares in the company, valued at approximately $4,299,998.56. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,329 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.64, for a total value of $52,065.56. Following the transaction, the senior vice president directly owned 258,352 shares of the company’s stock, valued at $4,040,625.28. This trade represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 46,590 shares of company stock valued at $765,137. Corporate insiders own 4.00% of the company’s stock.

SiBone Stock Performance

Shares of SiBone stock opened at $16.29 on Friday. The firm has a market cap of $702.75 million, a price-to-earnings ratio of -29.09 and a beta of 0.81. The stock’s 50-day moving average is $16.88 and its 200-day moving average is $16.50. SiBone has a one year low of $11.70 and a one year high of $20.05. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $48.63 million for the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. SiBone has set its FY 2025 guidance at EPS. Equities analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on SIBN shares. Cantor Fitzgerald set a $25.00 target price on SiBone and gave the company an “overweight” rating in a research note on Monday, August 11th. Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, SiBone has an average rating of “Buy” and an average price target of $23.67.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.